SII, Bharat Biotech to get bulk of Rs 15K-crore profit pool: Report

At present, SII sells its vaccine Covishield to the Centre for Rs 150 per dose, to state governments for Rs 300 and to private hospitals for Rs 600.

With India expected to spend Rs 75,000 crore (Centre, states and private sector) in calendar year 2021 on vaccines, including Rs 3,200 crore spent till April-end to combat Covid, Serum Institute of India (SII) and Bharat Biotech would be the key beneficiaries. According to an analyst report by Investec, Serum Institute and Bharat Biotech will control over 67 per cent (Serum Institute 43 per cent and Bharat Biotech 24 per cent) of the value market share and 73 per cent in terms of volumes. Sputnik V, the Russian Covid vaccine, will be the third player with a 14 per cent